Introduction 96 97
Multiple studies have documented the high intensity of medical care at the end of life, 1, 2 and there 98 is increasing consensus that such care can produce poor outcomes [2] [3] [4] and conflict with patient 99 preferences. 4, 5 The Institute of Medicine report Dying in America has drawn attention to the 100 difficulties of promoting palliative care, including Medicare's hospice program, 6 the nation's 101 largest palliative care intervention, which covers all comfort-oriented care related to terminal 102 illnesses, from medications to home care to hospitalizations. While the number of people 103 receiving hospice has increased since the program began in 1982, enrollment length decreased 104 over the same period, and end of life care intensity increased. 7 Patients with cancer, the single 105 largest group of hospice users, 8 have both the highest rates of hospice enrollment and the highest 106 rates of hospice stays under three days. Several policy factors are cited to explain these trends. First, the Medicare administration 109 monitors and prosecutes hospices with inappropriately long hospice stays, creating a perceived 110 disincentive for providers to make early hospice referrals that are more likely to produce long 111 stays.
9,10 Second, Medicare does not reimburse providers for discussions to elicit patients' 112 preferences for end of life care. 11 Third, Medicare requires patients to formally renounce curative 113 care before enrolling in hospice, which is thought to limit demand. 10, 12 This last issue is 114 particularly relevant to cancer care, since patients often wish to continue active treatment 115 irrespective of prognosis-an area of concern to payers as use of costly new targeted therapies, 116 often oral and less toxic, becomes widespread at the end of life. Indeed, many of these policies are related to concerns that increasing hospice use could increase 119 health care utilization and ultimately costs-while advocates of hospice argue that aggressive 120 end-of-life care outside of hospice is the more pressing cost issue. 10, 14 A key input to these 121 debates is a better understanding of the relationship between hospice and health care utilization, 122 and its implications for costs. To date, however, few studies have described the realities of how 123 hospice affects medical care at the end of life, and attempts to estimate cost savings have 124 produced mixed results, with two recent studies finding only small differences in costs that were 125 inconsistent across different lengths of hospice stays. 10, 15 Using data on Medicare beneficiaries 126 with poor-prognosis cancers, we matched those enrolled in hospice before death to those who 127 died without hospice care, and compared utilization and costs at the end of life. We created a list of International Classification of Disease (ICD) codes corresponding to poor-147 prognosis malignancies, derived from a palliative care screening instrument at a major US cancer 148 center, including poor-prognosis primaries (e.g., lung, pancreatic, brain), any metastatic or ill-149 defined malignancy, and hematologic malignancies designated as relapsed or not in remission 150 (eTable 1). 16 We retained beneficiaries with any of these codes present in claims between 2007-151 11 in the inpatient, outpatient, and carrier hospice files, excluding potential outpatient 'rule-out' 152 codes. 17 We attributed to hospice all care received by the beneficiary from enrollment (i.e., day of 153 first hospice claim) until death, and assumed beneficiaries remained in hospice until death; 98.6% 154 had a hospice claim within 30 days of death. We excluded those with hospice claims prior to 155 poor-prognosis cancer diagnoses, indicating enrollment for another, prior disease. 156
157
Matching 158
159
We used a two stage matching approach to create pairs of beneficiaries who were as similar as 160 possible, but made different choices regarding hospice enrollment at the same point in time 161 before death. First, we matched hospice beneficiaries to a control group of beneficiaries who did 162 not choose hospice. Second, for each matched pair, we matched the hospice period to the 163 equivalent 'exposure period' of non-hospice care before death. By matching hospice beneficiaries 164 to non-hospice beneficiaries, then comparing outcomes before and after hospice enrollment, we 165
attempted to capture what might have happened if the non-hospice beneficiary had instead 166 enrolled in hospice. 167
168
To match beneficiaries, we split the sample into those who enrolled in hospice at any time before 169 death, and those who did not. Our initial plan was to perform propensity score matching (PSM), 170 but this resulted in multiple significant imbalances between groups, which persisted despite 171 attempts to rematch on different covariates. As a result, we used coarsened exact matching 18 172 (CEM); we present these results here, and detailed PSM results in the supplement (eMethods). 173
We matched using four variables: place of residence, age, sex, and time from first poor-prognosis 174 cancer diagnosis to death. We assumed illness duration from diagnosis to death was inversely 175 correlated with disease severity and thus a good proxy measure for it; we also assumed that 176 hospice enrollment did not affect illness duration. We first matched on the finest strata of all 177 variables (home zip code, year of birth, sex, illness duration in months), then iteratively coarsened 178 variables and re-matched beneficiaries unmatched in the first round, to a maximum coarseness of 179 five-year age intervals, four-month illness duration intervals, and home hospital referral region 180 (HRR; see eTable2 19 We 201 calculated comorbidity over two periods: from the earliest data available (2006) 
Study population 223
In this nationally-representative 20% sample of Medicare fee-for-service beneficiaries with poor-225 prognosis cancer, median time from first poor-prognosis diagnosis to death was 13 months (IQR: 226 3-34); 60% received hospice care. Figure 1A shows creation of the matched cohort from this 227 population. Figure 1B shows creation of exposure periods, matching hospice periods to 228 equivalent periods of non-hospice care for matched controls. Of 86,851 deaths with poor-229 prognosis cancer, we matched 41,224 beneficiaries, or 59% of the smaller non-hospice group. 230
After hospice enrollment, 1% of hospice beneficiaries received cancer-directed therapy, 231 compared to 11% of non-hospice beneficiaries over similar exposure periods before death. Pairs 232 including these beneficiaries were excluded. The final cohort of 36,330 beneficiaries was largely 233 similar to the overall population of 86,851 cancer deaths from which it was drawn (eTable 4), but 234 had shorter median time from diagnosis to death (reflecting fewer exact matches on illness 235 duration among beneficiaries with longer survival times-eFigure 1), and lived in zip codes with 236 mean incomes 1-3% higher than the overall cohort. 237 238 Table 1 shows baseline characteristics of the matched cohort. There were no statistically-239 significant differences between cases and controls in age, sex, region, time from poor-prognosis 240 diagnosis to death, comorbidity before poor-prognosis diagnosis, or daily cost in the year before 241 hospice enrollment. Solid tumors accounted for the majority of diagnoses in both groups (91% 242 hospice, 88% non-hospice). Hospice beneficiaries were more white, and lived in higher-income 243 zip codes. Median hospice duration was 11 days; under 6% of stays exceeded six months. 244
Hospice and non-hospice beneficiaries had similar comorbidity before poor-prognosis diagnosis, 245 but higher comorbidity between diagnosis and hospice enrollment; illness duration from 246 diagnosis to death, however, was the same for both groups (7 months). Before exposure, hospice 247 beneficiaries had similar prevalence of dementia, anemia, fluid/electrolyte disturbances, 248 hemiplegia, and weight loss compared to non-hospice beneficiaries; hospice beneficiaries had 249 more days of home health assistance (7 vs. 6, difference: 1, 95% CI: 0. Table 2 compares health care utilization during hospice with the equivalent period before death 259 for matched non-hospice beneficiaries, in the last year of life. Non-hospice beneficiaries had 260 more hospitalizations, largely for acute conditions (e.g., infections, organ failure) and 261 exacerbations of medical comorbidities. Only one of the ten most frequent primary discharge 262 diagnoses involved cancer. Rates of intensive care and invasive procedures were also higher for 263 non-hospice beneficiaries. Seventy-four percent of non-hospice beneficiaries died in hospitals or 264
SNFs, compared to 14% of hospice. 265
266
We compared total costs for hospice and non-hospice beneficiaries before and after hospice start, 267 to capture overall intensity of care utilization, and yield insight into whether differences in 268 utilization were associated with hospice, or with pre-existing patient characteristics or care 269 preferences. In a matched cohort of Medicare beneficiaries with poor-prognosis cancers, we found large, 307 statistically-significant differences in care utilization between hospice and non-hospice 308 beneficiaries at the end of life. While enrolled in hospice, beneficiaries were hospitalized less, 309 received less intensive care, underwent fewer procedures, and were less likely to die in hospitals 310 and SNFs. Over similar periods before death, one in ten non-hospice beneficiaries received active 311 cancer-directed treatment; among those who did not, most were admitted to hospitals and ICUs 312 for acute conditions not directly related to their poor-prognosis cancer. Such care is unlikely to fit 313 with the preferences of most patients. Our findings highlight the potential importance of honest 314 discussions between doctors and patients about the realities of care at the end of life, an issue of 315 particular importance as the Medicare administration weighs decisions around reimbursing 316 providers for advance care planning. 317 318 Differences in care utilization between hospice and non-hospice beneficiaries translated into 319 statistically-significantly lower costs for hospice beneficiaries in the last year of life. Cost 320 trajectories began to diverge in the week after hospice enrollment, implying that baseline 321 differences between hospice and non-hospice beneficiaries were not responsible for cost 322 differences. Hospice enrollment of 5-8 weeks produced the greatest savings; shorter stays 323 produced fewer savings, likely because of both hospice initiation costs, and need for intensive 324 symptom palliation in the days before death. 24 Overall, these results may indicate that efforts to 325 promote broader and earlier hospice uptake are unlikely to produce increases in total costs. 326
Our study in no way replicates a randomized trial of a hospice intervention, and results depend on 328 the validity of the matching strategy, making it important to highlight key choices involved in the 329 creation of the study cohort. First, CEM achieved excellent balance for matched beneficiaries, but 330 failed to match a substantial number of beneficiaries (41% of the smaller non-hospice group, 53% 331 of the overall cohort). PSM matched 100% of the non-hospice group and 80% of the overall 332 cohort, but at the expense of inferior balance on important covariates. Each method had trade-offs 333 in terms of internal and external validity, but both ultimately produced very similar results. 334
Second, matching on illness duration made two crucial assumptions: that illness duration was a 335 proxy for disease severity, and that it was not affected by hospice enrollment. Matching on 336 duration would bias results if hospice prolonged life: hospice patients with more severe disease at 337 baseline, who improved after hospice treatment, would be matched to controls with less severe 338 baseline disease. Since utilization and severity are usually correlated, our estimates of differences 339 would be biased downward. If hospice beneficiaries had shorter survival, e.g., because of 340 discontinuation of effective anti-cancer treatment, the opposite would be true; but since cancer-341 directed therapy was more common for hospice beneficiaries before enrollment, insufficiently 342 aggressive treatment seems unlikely. Third, hospice beneficiaries had higher comorbidity scores 343 after poor-prognosis diagnoses, which could reflect higher overall utilization, or higher true 344 comorbidity. The latter would have biased downward our estimates of savings, though matching 345 on illness duration should have controlled for overall disease severity in this period. Fourth, our 346 results are unlikely to generalize to this sub-group of 1% of hospice beneficiaries who received 347 cancer-directed treatment after exposure start. Further, we could not determine if other hospice 348 beneficiaries left hospice. If this were widespread, contamination would lead to downward bias in 349 estimates of differences in outcomes. Finally, hospice beneficiaries lived in wealthier areas, 350 potentially giving them increased access to hospice. However, since pairs were matched by HRR, 351 geographic access to hospice should have been similar, except possibly in large-area rural HRRs. 352
353
There are other limitations to note. We restricted our analysis to beneficiaries with poor-prognosis 354 cancer, but non-cancer diagnoses are a growing part of the hospice population, and our results 355 may not generalize. We excluded beneficiaries with managed care, for whom claims data were 356 not available, and the entire non-Medicare population. We relied on ICD codes to identify poor-357 prognosis diagnoses, but claims-based diagnoses can be inaccurate. We determined place of death 358 via same-day facility claims, which did not include inpatient hospice facilities or assisted living; 359 we had incomplete data on SNF, and no data on personal care utilization. We did not include 360 outpatient medication expenses; these were likely lower in the hospice group, since hospice 361 covers medications related to their terminal condition. service beneficiaries who died in 2011, and restricting to those with a poor-prognosis 393 cancer diagnosis. Some beneficiaries were excluded because of missing data, and 394 others because they started hospice prior to cancer diagnosis, likely due to another 395 concurrent terminal illness. Panel B shows matching of exposure periods for two 396 hypothetical beneficiaries matched in the first stage. In chronological time, the two 397 beneficiaries are represented as lines spanning from poor-prognosis diagnosis to death; 398 in the exposure time frame used for analysis, dates of death are aligned to create a 399 similar exposure period of hospice or non-hospice care prior to death. Because 400 beneficiaries are matched on time from diagnosis to death, the lengths of the lines are 401 approximately the same. After matching exposure periods, we drop pairs in which one or 402 both beneficiaries received chemotherapy or curative surgery during the periods. 403 404 Figure 2 . Cost trajectories before and after hospice start 405 Figure 2 shows mean total daily costs relative to hospice start, with beneficiaries 406 separated into groups based on the length of the exposure period (i.e., the length of 407 hospice or non-hospice care before death). Since showing all 109 groups was not 408 possible, and since aggregation would obscure time trends, we show representative 409 groups with exposure periods of 1, 2, 3, and 4 weeks, which together make up 71% of 410 the entire cohort; every 2 weeks from 6 to 12 weeks (8% of the cohort); and every 4 411 weeks from 16 to 28 (2%). "X" marks week of death for each group of beneficiaries. The 412 panel title shows the length of the exposure period in weeks, the number of beneficiaries, 413 and the percentage of the overall matched cohort they make up. Table 2 shows health care utilization during exposure periods (i.e., hospice care, or the equivalent period before death for non-hospice beneficiaries) in the last year of life: percent of beneficiaries with hospital admission, ICU stay, procedure, and place of death, with 95% confidence intervals. The last column shows the ratio of hospice to non-hospice percentage, calculated as proportion of non-hospice over hospice beneficiaries, with 95% confidence interval (calculated as a relative risk). a Combines ICD codes 518.81 and 518.84 b Percent of beneficiaries with an inpatient facility claim on day of death. c Percent of beneficiaries with a claim from a long-term care hospital or skilled nursing facility on day of death. Data on SNFs are incomplete because of Medicare restrictions on the number of SNF days reimbursed per year, so these should be seen as minimum estimates for both groups. COPD denotes chronic obstructive pulmonary disease ICD denotes International Classification of Disease codes ICU denotes intensive care unit SNF denotes skilled nursing facility 
